Biohaven (BHVN) Earnings Analysis
Biohaven (BHVN) next reports earnings on 2026-08-10, consensus EPS -0.77 USD. Last quarter (2026-05-04) it missed with EPS -0.88 USD vs -0.86 USD est (-2.3%). It has beaten estimates in 3/6 recent quarters (50%). Trailing P/E -2.60.
Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades
When does BHVN next report earnings?
| Next earnings date | 2026-08-10 |
|---|---|
| Consensus EPS estimate | -0.77 USD |
| Revenue estimate | 0.00B |
BHVN earnings history — beats and misses
| Quarter (report date) | EPS actual | EPS est. | Surprise | Result |
|---|---|---|---|---|
| 2026-05-04 | -0.88 USD | -0.86 USD | -2.3% | Miss |
| 2026-03-02 | -1.21 USD | -1.22 USD | +0.8% | Beat |
| 2025-11-10 | -1.64 USD | -1.91 USD | +14.1% | Beat |
| 2025-08-11 | -1.94 USD | -1.94 USD | 0% | Beat |
| 2025-05-12 | -2.17 USD | -1.67 USD | -29.9% | Miss |
| 2025-03-03 | -1.85 USD | -1.56 USD | -18.6% | Miss |
Beat rate: 3/6 (50%) over reported quarters with consensus data.
BHVN valuation and analyst view
| Trailing P/E | -2.60 |
|---|---|
| Trailing EPS | -4.3876 USD |
| Price / book | 16.81 |
| Dividend yield | 0.00% |
| Market cap | 1.57B |
| Analyst consensus | Buy (17 buy / 7 hold / 1 sell) |
| Avg price target | 14.5 USD |
Related research pages
Frequently asked questions
When is Biohaven (BHVN)'s next earnings date?
Biohaven is next scheduled to report on 2026-08-10, with a consensus EPS estimate of -0.77 USD and revenue estimate of 0.00B.
Did BHVN beat earnings last quarter?
In its 2026-05-04 report, BHVN posted EPS of -0.88 USD versus a -0.86 USD estimate — a miss of 2.3%.
What is BHVN's earnings track record?
Over the last 6 reported quarters with consensus data, BHVN beat estimates 3 times (50%).
What is BHVN's current P/E ratio and EPS?
BHVN trades at a trailing P/E of -2.60 on trailing EPS of -4.387603804776279 USD.
What do analysts rate BHVN?
Analyst consensus is "Buy" across 25 ratings (0 strong buy, 17 buy, 7 hold, 1 sell, 0 strong sell). Average 12-month price target: 14.5 USD.